Antiplatelet therapy

Original Contribution

Toward Personalized DAPT: Is There an Inter-Manufacturer Difference in Generic Clopidogrel Response?

11/23/2022

Yuhe Xia , MS;

Hamza Ahmed , BS;

Daniela Iskhakov , PA-C;

Frederick Feit , MD;

Carlos L. Alviar , MD;

Norma Keller , MD;

Sripal Bangalore , MD, MHA;

Jeffrey S. Berger , MD, MS;

Sylvie Hall , PharmD, MPH;

This quality-improvement project included 515 adult patients receiving clopidogrel for ACS or ischemic heart disease and referred for coronary angiography/percutaneous coronary intervention. The project was divided into 2 phases: (1)...

This quality-improvement project...

11/23/2022

Journal of Invasive Cardiology

The Movement to Short-Infusion Tirofiban in the Cath Lab: the Next Leap in Practice Change

03/01/2018

Joseph Brent Muhlestein , MD, FAHA, FACC;

If patients are not already on dual antiplatelet therapy when they come in, achieving that status is going to take time and there is going to be a window in which they are not protected. One of the advantages of the short-term infusion of...

If patients are not already on...

03/01/2018

Cath Lab Digest

Original Contribution

Impact of Switching From Prasugrel to Clopidogrel Shortly After a Percutaneous Coronary Intervention Without a Loading Dose of Clopidogrel

09/15/2015

Mian Muhammad Ali Akram , MD;

Ibrahim Ismail-Sayed , MD;

Yvette M. Henry , PhD;

Melissa A. Troup ;

Peter B. Berger , MD;

Eddy Mizrahi , MD;

Ramya Smitha Suryadevara , MD;

Kulpreet Barn , MD;

Gouthami Boga , MD;

The authors present a retrospective analysis to determine the safety and efficacy of administering prasugrel at the time of percutaneous coronary intervention (PCI), and switching to clopidogrel, without reloading.

The authors present a...

09/15/2015

Journal of Invasive Cardiology

Delayed Clopidogrel Transit During Myocardial Infarction Evident on Angiography

04/29/2015

C. Michael Gibson , MS, MD;

Duane S. Pinto , MD, MPH;

Joanna Ghobrial , MD, MS;

We describe the case of a patient with NSTEMI where oral clopidogrel loading prior to PCI was directly visualized on angiography, implying a very low likelihood of adequate absorption or antiplatelet effect. This observation raises the...

We describe the case of a...

04/29/2015

Journal of Invasive Cardiology

Clinical Editor's Corner

Conversations in Cardiology: What to Do if Your Patient Can’t Take Aspirin After Stenting

10/15/2014

Morton J. Kern , MD, MSCAI, FACC, FAHA;

“I just put two drug-eluting stents into a native vessel and a distal graft anastomosis in a patient who is already on clopidogrel AND who has an aspirin allergy that cannot be touched or addressed. What additional drug, if any, would you...

“I just put two drug-eluting...

10/15/2014

Cath Lab Digest

Commentary

Optimal Antiplatelet Therapy: Lessons Learned from PCI Applicable to PAD and PPI

09/05/2008

David E. Allie , MD;

Patti et al. have further added to the mounting evidence that optimal antiplatelet therapy translates to clinical benefits in PCI by reporting the results of the ARMYDA-2 trial, which was a prospective, randomized trial between a pretreatment...

Patti et al. have further added...

09/05/2008

Vascular Disease Management

Original Contribution

Optimal Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: New Insights From the ARMYDA-2 Study

09/05/2008

Germano Di Sciascio , MD;

Percutaneous coronary intervention (PCI) with stenting has been shown to enhance platelet aggregation. Accordingly, optimization of antiplatelet therapy has a crucial role in patients undergoing percutaneous revascularization and even more...

Percutaneous coronary...

09/05/2008

Vascular Disease Management